Gyre Therapeutics, Inc.

NASDAQ:GYRE

Biotechnology

Healthcare
$4.34 -0.15%

+$0.00 today

Market cap
$475.02M
Beta
4.92
P/E (TTM)
-88.3
EPS (TTM)
-$0.07
52W Low $5.44High $9.42

Volume 0.47M

Average 0.09M

GYRE Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Gyre Therapeutics, Inc.NASDAQ: GYRE

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables growth accelerates

Q1 FY2026 accounts payables of $139K rose 892.9% year over year, ahead of the +166.3% change in trailing-twelve-month accounts payables.

Context

  • Accounts payables amounted to 0.0% of revenue in FY2025, down 0.2 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +892.9% holds above the trailing-twelve-month pace of +166.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$139K+132.1% QoQ
Last fiscal yearDec 2025
$13K+105.3% YoY
LTMMar 2026
$138K+166.3% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+892.9%——
1 year+105.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
13K USD
Year-over-year change
+105.3%
4-year CAGR
-59.8%

Accounts Payables vs competitors

How GYRE compares with its peers on the latest reported figures

  • GYRE's LTM Mar 2026 accounts payables of $138K is the smallest of the 4 companies compared; the peer median is $5.26M.
  • Its year-over-year change of +166.3% is the 2nd highest of 4, against a peer median of +89.5%.
  • Accounts payables amounts to 0.1% of revenue for GYRE, versus a peer median of 4.1%.
GYRE Competitors Peer median
Accounts Payables for GYRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GALTGalectin Therapeutics Inc.LTM Mar 2026$6.18M -986.9%——
PLRXPliant Therapeutics, Inc.LTM Mar 2026$5.26M +350.7%+59.5%—
SRZNSurrozen, Inc.LTM Mar 2026$307K +89.5%—4.1%
GYREGyre Therapeutics, Inc.LTM Mar 2026$138K +166.3%—0.1%
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding GYRE) $5.26M+89.5%+59.5%4.1%

Competitors are the stored peer set for GYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(87.93M)4.31M(85.48M)17.9M9.88M
Depreciation & Amortization290K1.13M1.11M1.59M2.48M
Deferred Income Tax(3.89M)(838K)(1.16M)(1M)(1.11M)
Stock-Based Compensation3.41M13.37M7.28M831K7.16M
Change in Working Capital483K(7.8M)7.46M(15.69M)(15.55M)
Accounts Receivables1.5M(7.92M)1.3M(9.29M)(11.95M)
Inventory3.88M(879K)1.75M(2.14M)(3.63M)
Accounts Payables500K(112K)192K(245K)13K
Other Working Capital(5.39M)1.11M4.22M(4.02M)17K
Other Non-Cash Items3.89M503K96.68M(7.27M)(1.85M)
Operating Cash Flow(83.76M)10.68M25.89M(3.64M)1.01M
Capital Expenditures(839K)(5M)(8.59M)(3.13M)(1.19M)
Acquisitions (Net)0(1.33M)4.02M(1.69M)30K
Purchases of Investments0(7.48M)(15.74M)(15.47M)0
Sales of Investments49.03M0000
Other Investing Activities0(13K)471K(412K)686K
Investing Cash Flow48.19M(13.81M)(19.76M)(19.88M)(474K)
Debt Repayment(6.7M)0000
Common Stock Issued49.55M00773K25.87M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities6.7M001.33M(1.49M)
Financing Cash Flow49.55M02.5M2.1M24.38M
Effect of Forex Changes0(1.89M)(298K)(273K)343K
Net Change in Cash13.99M(5.03M)8.33M(21.7M)25.26M
Free Cash Flow(84.59M)5.68M17.31M(6.77M)(180K)

Gyre Therapeutics, Inc.

NASDAQ:GYRE

Intrinsic Alpha fair value

Locked

Current Price

$4.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.